Bio-Rad expands product line by launching two human recombinant antigens

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced the launch of two human recombinant antigens, expanding the company's portfolio of Critical Raw Materials for the in vitro diagnostics market. These cell culture and recombinant antigens provide Bio-Rad customers with reliable critical assay components for use in lung and ovarian cancer diagnostics.

Bio-Rad's line of Critical Raw Materials are intermediate and semi-finished goods that are used for re-manufacture into standards, controls, calibrators as well as research into future assay development.

"Bio-Rad is pleased to offer an expanded product line to better support our valued customers," said Conrad Maurais, Product Manager, Bio-Rad "With the introduction of
the cell culture derived SCCA-1 and HE4 antigens we enable customers the opportunity to reduce their dependence upon antigens from human fluids and strengthen the integrity of their supply chain for these critical raw materials."

The New Antigens Include:

•HE4 Antigen: used as an aid in monitoring recurrence or progressive disease in patients with epithelial and endometrial ovarian cancer.

•Squamous Cell Carcinoma Antigen 1 (SCCA-1): used for detecting, staging and monitoring response to therapy in patients with squamous cell carcinoma of the lung.